Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose (Journal article)

Kostapanos, M. S./ Milionis, H. J./ Agouridis, A. D./ Rizos, C. V./ Elisaf, M. S.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorKostapanos, M. S.en
dc.contributor.authorMilionis, H. J.en
dc.contributor.authorAgouridis, A. D.en
dc.contributor.authorRizos, C. V.en
dc.contributor.authorElisaf, M. S.en
dc.rightsDefault Licence-
dc.subjectBlood Glucose/*drug effectsen
dc.subjectFluorobenzenes/*adverse effectsen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effectsen
dc.subjectHyperlipidemias/*drug therapyen
dc.subjectHypolipidemic Agents/*adverse effectsen
dc.subjectInsulin Resistance/*physiologyen
dc.subjectMiddle Ageden
dc.subjectPyrimidines/*adverse effectsen
dc.subjectSulfonamides/*adverse effectsen
dc.subjectYoung Adulten
dc.titleRosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucoseen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractAIM OF THE STUDY: The increase in physician-reported diabetes following rosuvastatin treatment in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study has raised concerns whether this statin exerts a detrimental effect on glucose metabolism. We assessed the effect of rosuvastatin treatment across dose range on glucose homeostasis in hyperlipidaemic patients with impaired fasting glucose (IFG), who are at high risk to develop diabetes mellitus. METHODS: The medical records of 72 hypelipidaemic patients with IFG on rosuvastatin 10 (RSV10 group), 20 (RSV20 group) and 40 mg/day (RSV40 group) were reviewed. The median follow up was 12.4 weeks. At the first visit, prior to rosuvastatin prescription and at the latest visit, serum lipid profile and indices of glucose metabolism, including fasting glucose, insulin and HOmeostasis Model Assessment (HOMA(IR)) index levels, were assessed. RESULTS: Rosuvastatin treatment improved lipid profile and was associated with a dose-dependent significant increase in HOMA(IR) values by 25.4%, 32.3% and 44.8% at the dose of 10, 20 and 40 mg/day (p < 0.01 for all, p < 0.05 for the comparison between groups), respectively, mirrored by correspondent increase in plasma insulin levels [by 21.7%, 25.7% and 46.2% in the RSV10, RSV20 and RSV40 group (p < 0.001 for all) respectively]. Baseline HOMA(IR) levels was the most important contributor (R(2) = 68.1%, p < 0.001), followed by the dose of rosuvastatin treatment (R(2) = 23.7%, p < 0.01), in a model that explained 91.8% of the variability in HOMA(IR) increase. CONCLUSION: In patients with IFG and hyperlipidaemia, rosuvastatin treatment was associated with a dose-dependent increase in insulin resistance.en
heal.journalNameInt J Clin Practen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Kostapanos-2009-Rosuvastatin treatme.pdf130.02 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.